The novel bifunctional anti‐PD‐L1/TGF‐βRII targeting fusion protein, SHR‐1701, has also shown early promise in refractory solid tumours, including pancreatic cancer [122, 124]. Here, CD274 is linked to pancreatic neoplasm.